Integra LifeSciences (IART) 10-Q 1 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 29, 2015
Document Documentand Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	iart
Entity Registrant Name	INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Central Index Key	917520
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		32,934,413

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Total revenue, net	$233,665	$215,059
Costs and expenses:
Cost of goods sold	86,722	82,383
Research and development	12,556	12,567
Selling, general and administrative	114,064	108,338
Intangible asset amortization	3,535	3,033
Total costs and expenses	216,877	206,321
Operating income	16,788	8,738
Interest income	5	62
Interest expense	-5,492	-5,142
Other income, net	1,316	317
Income before income taxes	12,617	3,975
Income tax expense	4,233	1,769
Net income	8,384	2,206
Basic net income per common share (in dollars per share)	$0.26	$0.07
Diluted net income per common share (in dollars per share)	$0.25	$0.07
Weighted average common shares outstanding (See Note 10):
Basic (in shares)	32,736	32,275
Diluted (in shares)	33,342	32,768
Comprehensive (loss) income (See Note 11)	($15,744)	$3,206

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$79,871	$71,994
Trade accounts receivable, net of allowances of $6,515 and $6,184	126,785	131,918
Inventories, net	233,043	237,114
Deferred tax assets	58,293	58,663
Prepaid expenses and other current assets	23,958	29,632
Total current assets	521,950	529,321
Property, plant and equipment, net	210,111	209,986
Intangible assets, net	447,424	459,459
Goodwill	354,202	363,888
Deferred tax assets	5,684	5,603
Other assets	11,436	10,368
Total assets	1,550,807	1,578,625
Current liabilities:
Borrowings under senior credit facility	5,625	3,750
Accounts payable, trade	42,630	34,060
Deferred revenue	4,303	5,176
Accrued compensation	33,209	40,943
Accrued expenses and other current liabilities	41,038	42,096
Total current liabilities	126,805	126,025
Long-term borrowings under senior credit facility	396,250	413,125
Long-term convertible securities	215,177	213,121
Deferred tax liabilities	92,431	91,623
Other liabilities	32,045	30,409
Total liabilities	862,708	874,303
Commitments and contingencies
Stockholders’ equity:
Preferred stock; no par value; 15,000 authorized shares; none outstanding	0	0
Common stock; $0.01 par value; 60,000 authorized shares; 41,755 and 41,644 issued at March 31, 2015 and December 31, 2014, respectively	418	416
Additional paid-in capital	779,074	779,555
Treasury stock, at cost; 8,903 shares at March 31, 2015 and December 31, 2014	-367,121	-367,121
Accumulated other comprehensive loss	-47,616	-23,488
Retained earnings	323,344	314,960
Total stockholders’ equity	688,099	704,322
Total liabilities and stockholders’ equity	$1,550,807	$1,578,625

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Trade accounts receivable, allowances	$6,515	$6,184
Preferred Stock, par value (in dollars per share)	$0	$0
Preferred Stock, authorized shares (in shares)	15,000,000	15,000,000
Preferred Stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	41,755,000	41,644,000
Treasury stock, shares (in shares)	8,903,000	8,903,000

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
OPERATING ACTIVITIES:
Net income	$8,384	$2,206
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	15,414	13,961
Non-cash impairment charges	409	600
Deferred income tax	1,184	1,563
Amortization of debt issuance costs	530	608
Non-cash interest expense	1,859	1,666
Gain on disposal of property and equipment	-19	0
Change in fair value of contingent consideration	125	128
Share-based compensation	2,377	2,471
Excess tax benefits from stock-based compensation arrangements	-1,121	-541
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	2,100	5,671
Inventories	-2,789	-8,516
Prepaid expenses and other current assets	6,003	-1,582
Other non-current assets	-1,730	-127
Accounts payable, accrued expenses and other current liabilities	-1,885	-4,438
Deferred revenue	-769	21
Other non-current liabilities	1,547	-2,437
Net cash provided by operating activities	31,619	11,254
INVESTING ACTIVITIES:
Purchases of property and equipment	-8,901	-11,335
Sale of property and equipment	1,438	0
Cash used in business acquisition, net of cash acquired	0	-235,000
Proceeds from working capital purchase price adjustment	1,831	0
Net cash used in investing activities	-5,632	-246,335
FINANCING ACTIVITIES:
Borrowings under senior credit facility	0	235,000
Repayments under senior credit facility	-15,000	0
Principal payments under capital lease obligations	-178	-122
Proceeds from exercised stock options	231	7,755
Excess tax benefits from stock-based compensation arrangements	1,121	541
Net cash (used in) provided by financing activities	-13,826	243,174
Effect of exchange rate changes on cash and cash equivalents	-4,284	331
Net change in cash and cash equivalents	7,877	8,424
Cash and cash equivalents at beginning of period	71,994	120,614
Cash and cash equivalents at end of period	$79,871	$129,038

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION
	General
	The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.
	In the opinion of management, the March 31, 2015 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K. The December 31, 2014 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three-month period ended March 31, 2015 are not necessarily indicative of the results to be expected for the entire year.
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including in-process research and development, amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of pension assets and liabilities, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
	Certain amounts from the prior year’s financial statements have been reclassified in order to conform to the current year’s presentation.
	Recently Issued Accounting Standards
	In April 2014, the FASB issued amendments to guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosures for individually significant dispositions that do not qualify as discontinued operations. The amendments are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The new guidance is effective for Integra prospectively for all disposals (or classifications as held for sale) of components of an entity that occur after January 1, 2015.
	In May 2014, the FASB issued Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should 1) identify the contract(s) with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. This update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early adoption is not permitted. The Company is in the process of evaluating the impact of this standard on its financial statements.
	In June 2014, the FASB issued Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (Topic 718). The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This update is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, and early adoption is permitted. The implementation of the amended guidance is not expected to have a material impact on our consolidated financial position or results of operations.
	In August 2014, the FASB issued Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendment requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. The implementation of the amended guidance is not expected to have an impact on current disclosures in the financial statements.
	In April 2015, the FASB issued Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendment requires that all costs incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard is limited to the presentation of debt issuance costs and does not affect the recognition or measurement of debt issuance costs. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on our consolidated results of operations and will result in a reclassification of our debt issuance costs from other long-term assets to long-term debt when adopted.
	There are no other recently issued accounting pronouncements that are expected to have a material effect on our financial position, results of operations or cash flows.

BUSINESS_ACQUISITIONS

BUSINESS ACQUISITIONS	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
BUSINESS ACQUISITIONS	BUSINESS ACQUISITIONS
	Metasurg
	On December 5, 2014, the Company acquired certain assets of Koby Ventures II, L.P. dba Metasurg ("Metasurg") for an aggregate purchase price of $27.2 million. The purchase price consists of an initial cash payment to Metasurg of $26.5 million and contingent consideration with an acquisition date fair value of $0.7 million. The potential maximum undiscounted contingent consideration of $38.5 million is based on reaching certain sales levels for acquired products from April 1, 2015 through June 30, 2016. The fair value of this liability is based on future sales projections of the Metasurg product under various potential scenarios and weighting the probability of these outcomes for the twelve-month period ended December 31, 2015. At the date of the acquisition, the cash flow projection was discounted using an internal rate of return of 19.9%. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement.
	Metasurg develops intuitive implant systems for the foot and ankle market and sells almost entirely in the U.S. market. The acquired foot and ankle products will enhance the Company's lower extremities market position.
	The Company recorded revenue for Metasurg of approximately $1.6 million in the condensed consolidated statements of operations for the three-month period ended March 31, 2015. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations.
	The following summarizes the preliminary allocation of the purchase price as of March 31, 2015 based on the fair value of the assets acquired and liabilities assumed:
		Preliminary
		Purchase Price
		Allocation
		(Dollars in thousands)
	Inventory	$	4,730
	Property, plant, and equipment	1,171
	Intangible assets:			Wtd. Avg. Life:
	Technology product rights	20,590		8 - 14 Years
	In-process research and development	190		Indefinite
	Goodwill	469
	Net assets acquired	$	27,150
	MicroFrance
	On October 27, 2014, the Company acquired all outstanding shares of Medtronic Xomed Instrumentation, SAS ("MicroFrance") from Medtronic, Inc. ("Medtronic") as well as certain assets of Medtronic for $60.1 million in cash (including working capital and purchase price adjustments of $1.5 million, of which $0.8 million was recorded against goodwill). MicroFrance specializes in manual ear, nose, and throat ("ENT") surgical instruments and designs, manufactures, and sells reusable handheld instruments to ENT and laparoscopy surgical specialists around the world. The acquired ENT instruments fill a portfolio gap for the Company with clear growth opportunities through market adjacencies and provides for increased scale and reach in the international market.
	The Company recorded revenue for MicroFrance of approximately $5.8 million in the condensed consolidated statements of operations for the three-month period ended March 31, 2015. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations.
	The Company adjusted the preliminary purchase price allocation during the quarter ended March 31, 2015 to reflect the $1.5 million working capital and purchase price adjustments. The following summarizes the preliminary allocation of the purchase price as of March 31, 2015 based on the fair value of the assets acquired and liabilities assumed:
		Preliminary
		Purchase Price
		Allocation
		(Dollars in thousands)
	Cash	$	2,195
	Inventory	3,155
	Prepaid expenses	620
	Property, plant, and equipment	3,675
	Other current assets	5,025
	Intangible assets:			Wtd. Avg. Life:
	Trade name	11,990		20 Years
	Technology	4,580		15 - 16 Years
	Customer relationships	18,130		12 - 16 Years
	Goodwill	16,607
	Total assets acquired	65,977
	Accounts payable and other liabilities	5,910
	Net assets acquired	$	60,067
	Confluent Surgical, Inc.
	On January 15, 2014, the Company acquired all outstanding shares of Confluent Surgical, Inc., ("Confluent Surgical") - including its surgical sealant and adhesion barrier product lines - from Covidien Group S.a.r.l, ("Covidien") for an aggregate purchase price of $255.9 million. The purchase price consists of an initial cash payment to Covidien of $231.0 million upon the closing of the transaction, a separate prepayment of $4.0 million made under a transitional supply agreement with an affiliate of Covidien, and contingent consideration with an acquisition date fair value of $20.9 million. The potential maximum undiscounted contingent consideration of $30.0 million consists of $25.0 million upon obtaining certain U.S. governmental approvals and $5.0 million upon obtaining certain European governmental approvals, both related to the completion of the transition of the Confluent Surgical business to the Company.
	The transitional supply agreement secures the supply of the acquired products from an affiliate of Covidien until the earlier of (i) the time that the transition of the Confluent Surgical business as discussed above is complete, or (ii) the fifth anniversary of the effective date of the agreement (the agreement also contains an option to extend for another two years by providing written notice at least 180 days prior to the end of the initial five-year period). This agreement contains financial incentives to the affiliate of Covidien for the timely supply of products each fiscal quarter through the third anniversary of the agreement. The prices paid under the supply agreement are essentially flat through the third anniversary of the agreement, and then increase significantly each of the following three years. The Company also entered into a transition services agreement with an affiliate of Covidien at the closing for services such as customer service, accounting and information technology management, clinical and regulatory affairs, manufacturing transition services, and other functions.
	This acquisition complements the Company's global neurosurgery growth strategy aimed at providing a broader set of solutions for surgical procedures in the head.
	The Company recorded revenue for Confluent Surgical of approximately $17.7 million and $14.1 million in the condensed consolidated statements of operations for the three-month periods ended March 31, 2015 and March 31, 2014, respectively. The net income or loss attributable to this acquisition cannot be identified on a stand-alone basis because it has been fully integrated into the Company's operations.
	The Company adjusted the preliminary purchase price allocation during the quarter ended June 30, 2014 to reduce deferred tax liabilities by $12.4 million. This adjustment offset goodwill and was the result of the Company analyzing and revising its tax positions in certain jurisdictions. The following summarizes the final allocation of the purchase price as of March 31, 2015 based on the fair value of the assets acquired and liabilities assumed:
		Final
		Purchase Price
		Allocation
		(Dollars in thousands)
	Inventory deposit	$	4,000
	Fixed assets	438
	Intangible assets:			Wtd. Avg. Life
	Technology product rights	239,800		3 - 20 Years
	Other	400		Less than 1 year
	Deferred tax assets - long term	12
	Goodwill	105,331
	Total assets acquired	349,981
	Contingent supply liability	5,891
	Other	731
	Deferred tax liabilities - long term	87,464
	Net assets acquired	$	255,895
	Subsequent to the acquisition date, a regulatory event occurred that resulted in the full-impairment of one of the acquired technology product rights of $0.6 million. This event was not known, or knowable, at the time of the acquisition and therefore the impairment has been included in the Company's cost of sales.
	The Company accounted for the contingent supply liability by recording its fair value as a liability on the date of the acquisition based on a discounted cash-flow model. This contingent supply liability relates to contractual quarterly incentive payments that will be made to an affiliate of Covidien if certain supply minimums under the transitional supply agreement are met.
	The Company accounted for the contingent consideration by recording its fair value as a liability on the date of the acquisition. The contingent consideration relates to the Company's obtaining certain U.S. and European regulatory approvals. At the date of the acquisition, both of these milestones were valued using a discount rate of 2.2%, which is equivalent to the cost of debt for the estimated time horizon, and an overall probability of occurring of 95%. Accordingly, on January 15, 2014 the Company recorded a $20.9 million liability representing the initial fair value estimate of the probability weighted contingent consideration that management believes will be paid between early 2017 and late 2018. Depending on the expected timing of the estimated payments, the acquisition date fair value of the probability adjusted payments could have been $0.3 million higher or $0.4 million lower. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. The contingent consideration is re-measured to fair value at each reporting date until the contingency is resolved, and those changes in fair value are recognized in earnings.
	The goodwill recorded in connection with these acquisitions is based on (i) expected cost savings, operating synergies and other benefits expected to result from the combined operations, (ii) the value of the going-concern element of the existing businesses (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately), and (iii) intangible assets that do not qualify for separate recognition such as an assembled workforce. The acquisitions generated a combination of deductible and non-deductible goodwill.
Contingent consideration
The Company increased the fair value of contingent consideration during the three-month period ended March 31, 2015 to reflect the change in the time value of money during the period. A reconciliation of the opening balances to the closing balances of these Level 3 measurements is as follows (in thousands):
			Location in Statement of Operations
Balance as of January 1, 2015	$	22,008
Loss from increase in fair value of contingent consideration liabilities	125		Selling, general and administrative
Fair value at March 31, 2015	$	22,133
The entire contingent consideration balance was included in Other liabilities at March 31, 2015 and December 31, 2014.
Pro Forma Results
The following unaudited pro forma financial information summarizes the results of operations for the three months ended March 31, 2014 as if the acquisitions completed by the Company during 2014 had been completed as of January 1, 2013. The pro forma results are based upon certain assumptions and estimates, and they give effect to actual operating results prior to the acquisition and adjustments to reflect (i) the change in interest expense, depreciation expense, and intangible asset amortization, (ii) certain external expenses related to the acquisition as if they were incurred on January 1, 2013 that will not be recurring in the post-acquisition periods, and (iii) income taxes on the aforementioned adjustments at the Company’s statutory rate. No effect has been given to other cost reductions or operating synergies. As a result, these pro forma results do not necessarily represent results that would have occurred if the acquisition had taken place on the basis assumed above, nor are they indicative of the results of future combined operations.
	Three Months Ended March 31, 2014
	(In thousands, except per share amounts)
Total revenue	$	225,509
Net income	$	5,572
Net income per share:
Basic	$	0.17

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2015
Inventory, Net [Abstract]
INVENTORIES	INVENTORIES
	Inventories, net consisted of the following:
		March 31, 2015		December 31, 2014
		(In thousands)
	Finished goods	$	143,866	$	150,483
	Work in process	53,168		50,166
	Raw materials	36,009		36,465
		$	233,043	$	237,114

GOODWILL_AND_OTHER_INTANGIBLE_

GOODWILL AND OTHER INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS
	In the first quarter of 2015 the Company revised its reportable segments in connection with the realignment of its portfolio. Specifically, the Company integrated the five existing business divisions into three global divisions, no longer focusing on international as a separate reportable segment but managing each business globally. The change in reportable segments resulted in the Company's requirement to reallocate existing goodwill to the new reportable segments based on the relative-fair-value of the Company's four underlying reporting units. With the reportable segments now being managed at a global level, goodwill previously assigned to the EMEA, LAPAC, and Private Label reporting units was reallocated to the new global reporting units. The Company estimated the fair value of the reporting units using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. Inputs used to fair value the Company's reporting units are considered inputs of the fair value hierarchy. For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement. The key assumptions impacting the valuation included the following:
	•	The reporting unit's financial projections, which are based on management's assessment of regional and macroeconomic variables, industry trends and market opportunities, and the Company's strategic objectives and future growth plans.
	•	The projected terminal value for the reporting unit, which represents the present value of projected cash flows beyond the last period in the discounted cash flow analysis. The terminal value reflects the Company's assumptions related to long-term growth rates and profitability, which are based on several factors, including local and macroeconomic variables, market opportunities, and future growth plans.
	•	The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data as well as the Company's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Company's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise.
	Based on the Company's fair value calculations, with the exception of the Spine reporting unit, given the excess of the Specialty Surgical Solutions Instruments, Specialty Surgical Solutions Neurosurgery, and Orthopedics and Tissue Technologies estimated fair value over their carrying value after the reallocation of goodwill, management concluded that any future goodwill impairment is not likely. The Company's allocation of goodwill to the Spine reporting unit has been impaired during the first quarter of 2015 as a result of the carrying value of its goodwill exceeding the implied fair value. Refer to Note 12 - Segment and Geographic Information for more information on the change in reportable segments.
	Changes in the carrying amount of goodwill for the three months ended March 31, 2015 were as follows:
		Specialty				Orthopedics and				Spine				Total
		Surgical				Tissue Technologies
		Solutions
		(In thousands)
	Goodwill, gross	$	281,829			$	81,650			$	409			$	363,888
	Accumulated impairment losses	—				—				—				—
	Goodwill at December 31, 2014	281,829				81,650				409				363,888
	MicroFrance working capital and purchase price adjustments	(828		)		—				—				(828		)
	Goodwill impairment charge	—				—				(409		)		(409		)
	Foreign currency translation	(6,433		)		(2,016		)		—				(8,449		)
	Balance, March 31, 2015	$	274,568			$	79,634			$	—			$	354,202
	The components of the Company’s identifiable intangible assets were as follows:
		31-Mar-15
		Weighted		Cost				Accumulated				Net
		Average						Amortization
		Life
		(Dollars in thousands)
	Completed technology	18 years		$	343,942			$	(67,172	)		$	276,770
	Customer relationships	12 years		158,546				(88,817		)		69,729
	Trademarks/brand names	34 years		42,713				(15,457		)		27,256
	Trademarks/brand names	Indefinite		48,484				—				48,484
	Supplier relationships	27 years		34,721				(11,166		)		23,555
	All other (1)	4 years		4,620				(2,990		)		1,630
				$	633,026			$	(185,602	)		$	447,424
		31-Dec-14
		Weighted		Cost				Accumulated				Net
		Average						Amortization
		Life
		(Dollars in thousands)
	Completed technology	18 years		$	345,082			$	(62,920	)		$	282,162
	Customer relationships	12 years		162,031				(87,653		)		74,378
	Trademarks/brand names	34 years		44,520				(15,755		)		28,765
	Trademarks/brand names	Indefinite		48,484				—				48,484
	Supplier relationships	27 years		34,721				(10,809		)		23,912
	All other (1)	4 years		4,810				(3,052		)		1,758
				$	639,648			$	(180,189	)		$	459,459
	(1)	At March 31, 2015 and December 31, 2014, all other included in-process research and development ("IPR&D") of $1.4 million in both periods, which was indefinite-lived.
	During the three months ended March 31, 2014, the Company recorded an impairment charge of $0.6 million in cost of goods sold related to technology assets acquired from Confluent Surgical that will no longer be sold resulting from a regulatory event that occurred after the acquisition date.
	Based on quarter-end exchange rates, annual amortization expense (including amounts reported in cost of product revenues, but excluding any possible future amortization associated with acquired in-process research and development) is expected to approximate $31.8 million in 2015, $29.6 million in 2016, $27.6 million in 2017, $27.2 million in 2018 and $26.5 million in 2019. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
DEBT	DEBT
	Amended and Restated Senior Credit Agreement
	On December 19, 2014, the Company entered into an amendment to the amended and restated credit agreement (the "Senior Credit Facility") which modified covenants to permit the distribution and/or dividend by the Company of its spine business to the Company's public stockholders. The intent of the amendment is to permit the Company to consummate the spine business spin-off transaction.
	On July 2, 2014, the Company entered into the Senior Credit Facility with a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Wells Fargo Bank, National Association, as Syndication Agent and HSBC Bank USA, National Association, Royal Bank of Canada, Citizens Bank, National Association, DNB Capital LLC, Credit Agricole-Corporate and Investment Bank and TD Bank, N.A., as Co-Documentation Agents. The Company's Senior Credit Facility was originally amended and restated on August 10, 2010, and that agreement was then amended on June 8, 2011, May 11, 2012, and June 21, 2013, as previously disclosed.
	The 2014 amended and restated Senior Credit Facility created an aggregate principal amount of up to $900.0 million available to the Company through the following facilities:
	i.	a $750.0 million revolving credit facility (increased from $600.0 million), which includes a $60.0 million sublimit for the issuance of standby letters of credit and a $60.0 million sublimit for swingline loans, and
	ii.	a $150.0 million term loan facility.
	The Senior Credit Facility allows the Company to further increase the size of either the revolving credit facility or the term loan facility, or a combination thereof, by an aggregate of $200.0 million with additional commitments. The July 2014 amended and restated Senior Credit Facility extended the maturity date of the prior facility from June 8, 2016 to July 2, 2019.
	Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to:
	i.	the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 1.75%), or
	ii.	the highest of:
	1	the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%, or
	2	the prime lending rate of Bank of America, N.A., or
	3	the one-month Eurodollar Rate plus 1.00%.
	The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness less cash in excess of $40.0 million that is not subject to any restriction of the use or investment thereof to (b) consolidated EBITDA) at the time of the applicable borrowing.
	The Company will also pay an annual commitment fee (ranging from 0.15% to 0.30%, based on the Company’s consolidated total leverage ratio) on the daily amount by which the revolving credit facility exceeds the outstanding loans and letters of credit under the credit facility.
	The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at March 31, 2015 the Company was in compliance with all such covenants. In connection with the modification of the 2014 amendment and restatement of the Senior Credit Facility the Company capitalized $3.2 million of incremental financing costs, and expensed $0.3 million of previously capitalized financing costs.
	On July 2, 2014, the Company borrowed $422.0 million under the Senior Credit Facility consisting of a $150.0 million term loan and $272.0 million under its revolving credit facility. The Company used the funds to repay the balance of its previous Senior Credit Facility. The outstanding borrowings have one, two, three, six months, or, if available, twelve months interest periods.
	At March 31, 2015 and December 31, 2014, there was $251.9 million and $266.9 million outstanding under the revolving credit component of the Senior Credit Facility at a weighted average interest rate of 1.7%. At March 31, 2015, there was approximately $498.1 million available for borrowing under the Senior Credit Facility. The Company considers the balance to be long-term in nature based on its current intent and ability to repay the borrowing outside of the next twelve-month period.
	At March 31, 2015 there was $150.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 1.7%. Contractual repayments of the term loan do not begin until September 30, 2015 and are due as follows:
	Year Ended December 31,		Principal Repayment
			(In thousands)
	2015		$	3,750
	2016		9,375
	2017		13,125
	2018		15,000
	2019		108,750
			$	150,000
	The fair value of outstanding borrowings of the Senior Credit Facility's revolving credit facility and term loan components at March 31, 2015 was approximately $235.8 million and $141.3 million, respectively. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
	2016 Convertible Senior Notes
	On June 15, 2011, the Company issued $230.0 million aggregate principal amount of its 1.625% Convertible Senior Notes due in 2016 (the “2016 Notes”). The 2016 Notes mature on December 15, 2016, and bear interest at a rate of 1.625% per annum payable semi-annually in arrears on December 15 and June 15 of each year. The portion of the debt proceeds that was classified as equity at the time of the offering was $43.2 million, an equivalent of that amount is being amortized to interest expense using the effective interest method through December 2016. The effective interest rate implicit in the liability component is 5.6%.
	At March 31, 2015, the carrying amount of the liability component was $215.2 million, the remaining unamortized discount was $14.8 million, and the principal amount outstanding was $230.0 million. The fair value of the 2016 Notes at March 31, 2015 was approximately $272.3 million. At December 31, 2014, the carrying amount of the liability component was $213.1 million, the remaining unamortized discount was $16.9 million and the principal amount outstanding was $230.0 million. The fair value of the liability of the 2016 Notes was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2.
	The 2016 Notes are senior, unsecured obligations of the Company, and are convertible into cash and, if applicable, shares of its common stock based on an initial conversion rate, subject to adjustment of 17.4092 shares per $1,000 principal amount of 2016 Notes (which represents an initial conversion price of approximately $57.44 per share). The Company will satisfy any conversion of the 2016 Notes with cash up to the principal amount of the 2016 Notes pursuant to the net share settlement mechanism set forth in the indenture and, with respect to any excess conversion value, with shares of the Company’s common stock. The 2016 Notes are convertible only in the following circumstances: (1) if the closing sale price of the Company’s common stock exceeds 150% of the conversion price during a period as defined in the indenture; (2) if the average trading price per $1,000 principal amount of the 2016 Notes is less than or equal to 98% of the average conversion value of the 2016 Notes during a period as defined in the indenture; (3) at any time on or after June 15, 2016; or (4) if specified corporate transactions occur. The issue price of the 2016 Notes was equal to their face amount, which is also the amount holders are entitled to receive at maturity if the 2016 Notes are not converted. As of March 31, 2015, certain conversion features were triggered due to the proposed spin-off of the Company's subsidiary, Seaspine Holdings Corporation, which allows the holders to convert all or any of the 2016 Notes subject to certain conditions.  The 2016 Notes are convertible through June 10, 2015. However, the Company has continued to classify these notes as long-term as of March 31, 2015, as the Company has the intent and ability to refinance the 2016 Notes.
	In connection with the issuance of the 2016 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of such notes (the “hedge participants”). The initial strike price of the call transaction is approximately $57.44 per share, subject to customary anti-dilution adjustments. The initial strike price of the warrant transaction is approximately $70.05 per share, subject to customary anti-dilution adjustments.
	Convertible Note Interest
	The interest expense components of the Company’s convertible notes are as follows (net of capitalized interest amounts):
		Three Months Ended March 31,
		2015			2014
		(In thousands)
	2016 Notes:
	Amortization of the discount on the liability component	$	1,859		$	1,666
	Cash interest related to the contractual interest coupon	845			801
	Total	$	2,704		$	2,467

DERIVATIVE_INSTRUMENTS

DERIVATIVE INSTRUMENTS	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS	DERIVATIVE INSTRUMENTS
	Interest Rate Hedging
	The Company’s interest rate risk relates to U.S. dollar denominated variable LIBOR interest rate borrowings. The Company uses an interest rate swap derivative instrument entered into on August 10, 2010 with an effective date of December 31, 2010 to manage its earnings and cash flow exposure to changes in interest rates by converting a portion of its floating-rate debt into fixed-rate debt beginning on December 31, 2010. This interest rate swap expires on August 10, 2015.
	The Company designates this derivative instrument as a cash flow hedge. The Company records the effective portion of any change in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax, until the hedged item affects earnings, at which point the effective portion of any gain or loss will be reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time.
	The Company expects that approximately $0.5 million of pre-tax losses recorded as net in AOCI related to the interest rate hedge could be reclassified to earnings within the next twelve months.
	Foreign Currency Hedging
	From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company records the effective portion of any change in the fair value of foreign currency cash flow hedges in AOCI, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies the effective portion of any related unrealized gain or loss on the foreign currency cash flow hedge to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time.
	The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in euros. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect its earnings and cash flows.
	There were no contracts outstanding as of March 31, 2015.
	Counterparty Credit Risk
	The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.
	Fair Value of Derivative Instruments
	The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair value of the foreign currency forward exchange contracts related to inventory purchases is determined by comparing the forward rate as of the period end and the settlement rate specified in each contract. The fair value of the interest rate swaps was developed using a market approach based on publicly available market yield curves and the terms of the related swap. The Company performs ongoing assessments of counterparty credit risk.
	The following table summarizes the fair value and presentation for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of March 31, 2015 and December 31, 2014:
			Fair Value as of
	Location on Balance Sheet (1):		March 31, 2015			December 31, 2014
			(In thousands)
	Derivatives designated as hedges — Liabilities:
	Interest rate swap — Accrued expenses and other current liabilities (2)		$	527		$	898
	Total Derivatives designated as hedges — Liabilities		$	527		$	898
	(1)	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
	(2)	At March 31, 2015 and December 31, 2014, the notional amount related to the Company’s sole interest rate swap was $93.8 million and $97.5 million, respectively. In the next twelve months, the Company expects to reduce the notional amount by the entire $93.8 million.
	The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statements of operations during the three months ended March 31, 2015 and 2014:
		Balance in AOCI			Amount of			Amount of Loss			Balance in AOCI			Location in
		Beginning of			Loss			Reclassified from			End of Quarter			Statements of
		Quarter			Recognized in			AOCI into						Operations
					AOCI-			Earnings-Effective
					Effective Portion			Portion
		(In thousands)
	Three Months Ended March 31, 2015
	Interest rate swap	(898		)	(18		)	(389		)	(527		)	Interest (expense)
		$	(898	)	$	(18	)	$	(389	)	$	(527	)
	Three Months Ended March 31, 2014
	Interest rate swap	(2,439		)	(109		)	(451		)	(2,097		)	Interest (expense)
		$	(2,439	)	$	(109	)	$	(451	)	$	(2,097	)
	The Company recognized no gains or losses resulting from ineffectiveness of cash flow hedges during the three months ended March 31, 2015 and 2014.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION
	As of March 31, 2015, the Company had stock options, restricted stock awards, performance stock units, contract stock awards and restricted stock unit awards outstanding under three plans, the 2000 Equity Incentive Plan (the “2000 Plan”), the 2001 Equity Incentive Plan (the “2001 Plan”), and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, the “Plans”).
	Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers, directors, and employees, and generally expire eight years from the grant date for employees, and from eight to ten years for directors and certain executive officers. Restricted stock issued under the Plans vests over specified periods, generally three years after the date of grant. The vesting of performance stock, issued under the Plans, is subject to service and performance conditions.
	Stock Options
	As of March 31, 2015, there were approximately $2.7 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately three years. There were 78,336 stock options granted during the three months ended March 31, 2015.
	Awards of Restricted Stock, Performance Stock and Contract Stock
	Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. Performance stock units are subject to graded vesting conditions and the Company expenses their fair value over the requisite service period. The Company expenses the fair value of restricted stock and contract stock awards on a straight-line basis over the vesting period or requisite service period, whichever is shorter. As of March 31, 2015, there were approximately $20.3 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company granted 117,763 restricted stock awards/stock units and 64,770 performance shares during the three months ended March 31, 2015.
	The Company has no formal policy related to the repurchase of shares for the purpose of satisfying stock-based compensation obligations.
	The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.

TREASURY_STOCK

TREASURY STOCK	3 Months Ended
	Mar. 31, 2015
Treasury Stock Transactions, Excluding Value of Shares Reissued [Abstract]
TREASURY STOCK	TREASURY STOCK
	On October 28, 2014, the Board of Directors terminated the October 2012 authorization and authorized up to $75.0 million of its outstanding common stock through December 2016. The Company has not repurchased any of its outstanding shares of common stock during the three-month periods ended March 31, 2015 and 2014. As of March 31, 2015, there remained $75.0 million available for repurchases under this authorization.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES
	The following table provides a summary of the Company’s effective tax rate:
		Three Months Ended March 31,
		2015		2014
	Reported tax rate	33.5	%	44.5	%
	The Company’s effective income tax rates for the three months ended March 31, 2015 and 2014 were 33.5% and 44.5%, respectively. The primary driver of the higher tax rate for the three months ended March 31, 2014 compared to the three months ended March 31, 2015 was a tax expense of $0.8 million relating to foreign and state income tax audit settlements.
	The Company expects its effective income tax rate for the full year to be approximately 29% to 30%, resulting largely from nondeductible spine spin-off costs and audit settlements offset by the release of uncertain tax positions, as well as the jurisdictional mix of pretax income in U.S.-based operations relative to foreign operations. This estimate could be revised in the future as additional information is presented to the Company.

NET_INCOME_PER_SHARE

NET INCOME PER SHARE	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NET INCOME PER SHARE
	Basic and diluted net income per share was as follows:
		Three Months Ended March 31,
		2015		2014
		(In thousands, except per share amounts)
	Basic net income per share:
	Net income	$	8,384	$	2,206
	Weighted average common shares outstanding	32,736		32,275
	Basic net income per common share	$	0.26	$	0.07
	Diluted net income per share:
	Net income	$	8,384	$	2,206
	Weighted average common shares outstanding — Basic	32,736		32,275
	Effect of dilutive securities:
	2016 Convertible notes	30		—
	Stock options and restricted stock	576		493
	Weighted average common shares for diluted earnings per share	33,342		32,768
	Diluted net income per common share	$	0.25	$	0.07
	At March 31, 2015 and 2014, the Company had 1.3 million and 1.4 million of outstanding stock options, respectively. The Company also has warrants outstanding relating to its 2016 Notes at March 31, 2015 and 2014 and the Company's 2016 Notes are convertible to common shares in certain circumstances (see Note 5). Stock options, restricted stock, warrants and the excess conversion value of the 2016 Notes are included in the diluted earnings per share calculation using the treasury stock method, unless the effect of including such items would be anti-dilutive.
	For the three months ended March 31, 2015, a minimal amount of anti-dilutive stock options were excluded from the diluted earnings per share calculation. For the three months ended March 31, 2014, 0.2 million of anti-dilutive stock options were excluded from the diluted earnings per share calculation. The effect of outstanding warrants were anti-dilutive because the strike price of the warrants exceeded the Company’s average stock price for the periods presented. The potential excess conversion value of the 2016 Notes were anti-dilutive because the conversion price exceeded the Company's stock price for the three months ended March 31, 2014; therefore, these amounts have been excluded from the diluted earnings per share calculation. However, for the three months ended March 31, 2015, the potential excess conversion value was included in the Company's dilutive share calculation because the average stock price for the three months ended March 31, 2015 exceeded the conversion price.

COMPREHENSIVE_LOSS_INCOME

COMPREHENSIVE (LOSS) INCOME	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
COMPREHENSIVE (LOSS) INCOME	COMPREHENSIVE (LOSS) INCOME
	Comprehensive (loss) income was as follows:
		Three Months Ended March 31,
		2015				2014
		(In thousands)
	Net income	$	8,384			$	2,206
	Foreign currency translation adjustment	(24,393		)		819
	Change in unrealized gain on derivatives, net of tax	211				195
	Pension liability adjustment, net of tax	54				(14		)
	Comprehensive (loss) income	$	(15,744	)		$	3,206
	Changes in Accumulated Other Comprehensive Loss by component between December 31, 2014 and March 31, 2015 are presented in the table below, net of tax:
			Gains and (Losses) on Cash Flow Hedges				Defined Benefit Pension Items			Foreign Currency Items			Total
			(In thousands)
	Beginning balance		$	(512	)		$	(906	)	$	(22,070	)	$	(23,488	)
	Other comprehensive income before reclassifications		(10		)		54			(24,393		)	(24,349		)
	Amounts reclassified from accumulated other comprehensive income		221				—			—			221
	Net current-period other comprehensive income		211				54			(24,393		)	(24,128		)
	Ending balance		$	(301	)		$	(852	)	$	(46,463	)	$	(47,616	)
	The reclassification adjustments out of Accumulated Other Comprehensive Loss during the three months ended March 31, 2015 were as follows:
	Three Months Ended March 31, 2015
	Details about Accumulated Other Comprehensive Income (Loss) Components		Amount Reclassified from Accumulated Other Comprehensive Income (Loss)				Affected Line Item in the Statement where Net Income (Loss) is Presented
			(In thousands)
	Gains and losses on cash flow hedges
	Interest rate swap		$	(388	)		Interest (expense)
			167				Tax (expense) or benefit
			$	(221	)		Net of tax

SEGMENT_AND_GEOGRAPHIC_INFORMA

SEGMENT AND GEOGRAPHIC INFORMATION	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATION
	Starting in the first quarter of 2015, because of changes in how the Company internally manages and reports the results of its businesses to its chief operating decision maker, the Company is disclosing three global reportable segments. The three global reportable segments and their activities are described below, as follows:
	•	The Specialty Surgical Solutions segment includes (i) the Neurosurgery business which sells a full line of products specifically for neurosurgery and critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business which sells more than 60,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.
	•	The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation, implants in the upper and lower extremities, bone grafts and nerve and tendon repair.
	•	The Spine segment focuses on spinal fusion, spinal implants, and deformity correction, together with bone graft substitutes and other related medical devices that are used to enhance the repair and regeneration of bone in various types of orthopedic surgical procedures.
	The most notable change from the Company's financial statements for the year ended December 31, 2014 included in the Annual Report on Form 10-K is the integration of the former International reportable segment into the segments noted above as well as the Private Label segment into Orthopedics and Tissue Technologies and Spine.
	The Corporate and other category includes (i) various legal, finance, information systems, executive, and human resource functions, (ii) brand management, and (iii) share-based compensation costs. Prior to the realignment, costs related to procurement, manufacturing operations and logistics for the Company's entire organization were not allocated to operating segments. In connection with the realignment, a portion of these costs have now been incorporated into the disclosed operating segments.
	The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the three months ended March 31, 2015 and 2014 are as follows:
			Three Months Ended March 31,
			2015				2014
			(In thousands)
	Segment Net Sales
	Specialty Surgical Solutions		$	140,058			$	127,195
	Orthopedics and Tissue Technologies		61,367				54,589
	Spine		32,240				33,275
	Total revenues		$	233,665			$	215,059
	Segment Profit
	Specialty Surgical Solutions		$	60,332			$	48,297
	Orthopedics and Tissue Technologies		19,582				17,001
	Spine		3,125				2,748
	Segment profit		83,039				68,046
	Amortization		(3,535		)		-3,033
	Corporate and other		(62,716		)		(56,275		)
	Operating income (loss)		$	16,788			$	8,738
	The Company attributes revenues to geographic areas based on the location of the customer. There are certain revenues managed by the various U.S. segments that are generated from non-U.S. customers and therefore are included in Europe and the Rest of World revenues below. Total revenue by major geographic area consisted of the following:
		Three Months Ended March 31,
		2015				2014
		(In thousands)
	United States	$	180,960			$	163,382
	Europe	26,764				25,324
	Rest of World	25,941				26,353
	Total Revenues	$	233,665			$	215,059

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES
	In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
	The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on our financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
	The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.

BASIS_OF_PRESENTATION_Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards
	In April 2014, the FASB issued amendments to guidance for reporting discontinued operations and disposals of components of an entity. The amended guidance requires that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosures for individually significant dispositions that do not qualify as discontinued operations. The amendments are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2014 (early adoption is permitted only for disposals that have not been previously reported). The new guidance is effective for Integra prospectively for all disposals (or classifications as held for sale) of components of an entity that occur after January 1, 2015.
	In May 2014, the FASB issued Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should 1) identify the contract(s) with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. This update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early adoption is not permitted. The Company is in the process of evaluating the impact of this standard on its financial statements.
	In June 2014, the FASB issued Update No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (Topic 718). The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This update is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, and early adoption is permitted. The implementation of the amended guidance is not expected to have a material impact on our consolidated financial position or results of operations.
	In August 2014, the FASB issued Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendment requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2016. The implementation of the amended guidance is not expected to have an impact on current disclosures in the financial statements.
	In April 2015, the FASB issued Update No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendment requires that all costs incurred to issue debt be presented in the balance sheet as a direct deduction from the carrying value of the debt. The new standard is limited to the presentation of debt issuance costs and does not affect the recognition or measurement of debt issuance costs. This update will become effective for all annual periods and interim reporting periods beginning after December 15, 2015. The implementation of the amended guidance is not expected to have a material impact on our consolidated results of operations and will result in a reclassification of our debt issuance costs from other long-term assets to long-term debt when adopted.
	There are no other recently issued accounting pronouncements that are expected to have a material effect on our financial position, results of operations or cash flows.

BUSINESS_ACQUISITIONS_Tables

BUSINESS ACQUISITIONS (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Schedule of Purchase Price Allocation	The following summarizes the preliminary allocation of the purchase price as of March 31, 2015 based on the fair value of the assets acquired and liabilities assumed:
		Preliminary
		Purchase Price
		Allocation
		(Dollars in thousands)
	Inventory	$	4,730
	Property, plant, and equipment	1,171
	Intangible assets:			Wtd. Avg. Life:
	Technology product rights	20,590		8 - 14 Years
	In-process research and development	190		Indefinite
	Goodwill	469
	Net assets acquired	$	27,150
	The following summarizes the final allocation of the purchase price as of March 31, 2015 based on the fair value of the assets acquired and liabilities assumed:
		Final
		Purchase Price
		Allocation
		(Dollars in thousands)
	Inventory deposit	$	4,000
	Fixed assets	438
	Intangible assets:			Wtd. Avg. Life
	Technology product rights	239,800		3 - 20 Years
	Other	400		Less than 1 year
	Deferred tax assets - long term	12
	Goodwill	105,331
	Total assets acquired	349,981
	Contingent supply liability	5,891
	Other	731
	Deferred tax liabilities - long term	87,464
	Net assets acquired	$	255,895
	The following summarizes the preliminary allocation of the purchase price as of March 31, 2015 based on the fair value of the assets acquired and liabilities assumed:
		Preliminary
		Purchase Price
		Allocation
		(Dollars in thousands)
	Cash	$	2,195
	Inventory	3,155
	Prepaid expenses	620
	Property, plant, and equipment	3,675
	Other current assets	5,025
	Intangible assets:			Wtd. Avg. Life:
	Trade name	11,990		20 Years
	Technology	4,580		15 - 16 Years
	Customer relationships	18,130		12 - 16 Years
	Goodwill	16,607
	Total assets acquired	65,977
	Accounts payable and other liabilities	5,910
	Net assets acquired	$	60,067
Schedule of Contingent Consideration	A reconciliation of the opening balances to the closing balances of these Level 3 measurements is as follows (in thousands):
				Location in Statement of Operations
	Balance as of January 1, 2015	$	22,008
	Loss from increase in fair value of contingent consideration liabilities	125		Selling, general and administrative
	Fair value at March 31, 2015	$	22,133
Pro Forma Information	As a result, these pro forma results do not necessarily represent results that would have occurred if the acquisition had taken place on the basis assumed above, nor are they indicative of the results of future combined operations.
		Three Months Ended March 31, 2014
		(In thousands, except per share amounts)
	Total revenue	$	225,509
	Net income	$	5,572
	Net income per share:
	Basic	$	0.17

INVENTORIES_Tables

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory, Net [Abstract]
Schedule of Inventory, Net	Inventories, net consisted of the following:
		March 31, 2015		December 31, 2014
		(In thousands)
	Finished goods	$	143,866	$	150,483
	Work in process	53,168		50,166
	Raw materials	36,009		36,465
		$	233,043	$	237,114

GOODWILL_AND_OTHER_INTANGIBLE_1

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes In Carrying Amount Of Goodwill	Changes in the carrying amount of goodwill for the three months ended March 31, 2015 were as follows:
		Specialty				Orthopedics and				Spine				Total
		Surgical				Tissue Technologies
		Solutions
		(In thousands)
	Goodwill, gross	$	281,829			$	81,650			$	409			$	363,888
	Accumulated impairment losses	—				—				—				—
	Goodwill at December 31, 2014	281,829				81,650				409				363,888
	MicroFrance working capital and purchase price adjustments	(828		)		—				—				(828		)
	Goodwill impairment charge	—				—				(409		)		(409		)
	Foreign currency translation	(6,433		)		(2,016		)		—				(8,449		)
	Balance, March 31, 2015	$	274,568			$	79,634			$	—			$	354,202
Components of Company's Identifiable Intangible Assets	The components of the Company’s identifiable intangible assets were as follows:
		31-Mar-15
		Weighted		Cost				Accumulated				Net
		Average						Amortization
		Life
		(Dollars in thousands)
	Completed technology	18 years		$	343,942			$	(67,172	)		$	276,770
	Customer relationships	12 years		158,546				(88,817		)		69,729
	Trademarks/brand names	34 years		42,713				(15,457		)		27,256
	Trademarks/brand names	Indefinite		48,484				—				48,484
	Supplier relationships	27 years		34,721				(11,166		)		23,555
	All other (1)	4 years		4,620				(2,990		)		1,630
				$	633,026			$	(185,602	)		$	447,424
		31-Dec-14
		Weighted		Cost				Accumulated				Net
		Average						Amortization
		Life
		(Dollars in thousands)
	Completed technology	18 years		$	345,082			$	(62,920	)		$	282,162
	Customer relationships	12 years		162,031				(87,653		)		74,378
	Trademarks/brand names	34 years		44,520				(15,755		)		28,765
	Trademarks/brand names	Indefinite		48,484				—				48,484
	Supplier relationships	27 years		34,721				(10,809		)		23,912
	All other (1)	4 years		4,810				(3,052		)		1,758
				$	639,648			$	(180,189	)		$	459,459
	(1)	At March 31, 2015 and December 31, 2014, all other included in-process research and development ("IPR&D") of $1.4 million in both periods, which was indefinite-lived.

DEBT_Tables

DEBT (Tables)	3 Months Ended
	Mar. 31, 2015
Term loan maturities [Line Items]
Components of Interest Expense	The interest expense components of the Company’s convertible notes are as follows (net of capitalized interest amounts):
		Three Months Ended March 31,
		2015			2014
		(In thousands)
	2016 Notes:
	Amortization of the discount on the liability component	$	1,859		$	1,666
	Cash interest related to the contractual interest coupon	845			801
	Total	$	2,704		$	2,467
Term Loan
Term loan maturities [Line Items]
Schedule of Maturities of Long-term Debt	At March 31, 2015 there was $150.0 million outstanding under the term loan component of the Senior Credit Facility at a weighted average interest rate of 1.7%. Contractual repayments of the term loan do not begin until September 30, 2015 and are due as follows:
	Year Ended December 31,		Principal Repayment
			(In thousands)
	2015		$	3,750
	2016		9,375
	2017		13,125
	2018		15,000
	2019		108,750
			$	150,000

DERIVATIVE_INSTRUMENTS_Tables

DERIVATIVE INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Value In Balance Sheet For Derivatives Designated As Hedging Instruments	The following table summarizes the fair value and presentation for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of March 31, 2015 and December 31, 2014:
			Fair Value as of
	Location on Balance Sheet (1):		March 31, 2015			December 31, 2014
			(In thousands)
	Derivatives designated as hedges — Liabilities:
	Interest rate swap — Accrued expenses and other current liabilities (2)		$	527		$	898
	Total Derivatives designated as hedges — Liabilities		$	527		$	898
	(1)	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
	(2)	At March 31, 2015 and December 31, 2014, the notional amount related to the Company’s sole interest rate swap was $93.8 million and $97.5 million, respectively. In the next twelve months, the Company expects to reduce the notional amount by the entire $93.8 million
Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations	The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying condensed consolidated statements of operations during the three months ended March 31, 2015 and 2014:
		Balance in AOCI			Amount of			Amount of Loss			Balance in AOCI			Location in
		Beginning of			Loss			Reclassified from			End of Quarter			Statements of
		Quarter			Recognized in			AOCI into						Operations
					AOCI-			Earnings-Effective
					Effective Portion			Portion
		(In thousands)
	Three Months Ended March 31, 2015
	Interest rate swap	(898		)	(18		)	(389		)	(527		)	Interest (expense)
		$	(898	)	$	(18	)	$	(389	)	$	(527	)
	Three Months Ended March 31, 2014
	Interest rate swap	(2,439		)	(109		)	(451		)	(2,097		)	Interest (expense)
		$	(2,439	)	$	(109	)	$	(451	)	$	(2,097	)

INCOME_TAXES_Tables

INCOME TAXES (Tables)	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of effective income tax rate reconciliation	The following table provides a summary of the Company’s effective tax rate:
		Three Months Ended March 31,
		2015		2014
	Reported tax rate	33.5	%	44.5	%

NET_INCOME_PER_SHARE_Tables

NET INCOME PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	Basic and diluted net income per share was as follows:
		Three Months Ended March 31,
		2015		2014
		(In thousands, except per share amounts)
	Basic net income per share:
	Net income	$	8,384	$	2,206
	Weighted average common shares outstanding	32,736		32,275
	Basic net income per common share	$	0.26	$	0.07
	Diluted net income per share:
	Net income	$	8,384	$	2,206
	Weighted average common shares outstanding — Basic	32,736		32,275
	Effect of dilutive securities:
	2016 Convertible notes	30		—
	Stock options and restricted stock	576		493
	Weighted average common shares for diluted earnings per share	33,342		32,768
	Diluted net income per common share	$	0.25	$	0.07

COMPREHENSIVE_LOSS_INCOME_Tabl

COMPREHENSIVE (LOSS) INCOME (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Schedule of Comprehensive (Loss) Income	Comprehensive (loss) income was as follows:
		Three Months Ended March 31,
		2015				2014
		(In thousands)
	Net income	$	8,384			$	2,206
	Foreign currency translation adjustment	(24,393		)		819
	Change in unrealized gain on derivatives, net of tax	211				195
	Pension liability adjustment, net of tax	54				(14		)
	Comprehensive (loss) income	$	(15,744	)		$	3,206
Schedule of Changes in Accumulated Other Comprehensive Income by Component	Changes in Accumulated Other Comprehensive Loss by component between December 31, 2014 and March 31, 2015 are presented in the table below, net of tax:
			Gains and (Losses) on Cash Flow Hedges				Defined Benefit Pension Items			Foreign Currency Items			Total
			(In thousands)
	Beginning balance		$	(512	)		$	(906	)	$	(22,070	)	$	(23,488	)
	Other comprehensive income before reclassifications		(10		)		54			(24,393		)	(24,349		)
	Amounts reclassified from accumulated other comprehensive income		221				—			—			221
	Net current-period other comprehensive income		211				54			(24,393		)	(24,128		)
	Ending balance		$	(301	)		$	(852	)	$	(46,463	)	$	(47,616	)
Reclassification out of Accumulated Other Comprehensive Income (Loss)	The reclassification adjustments out of Accumulated Other Comprehensive Loss during the three months ended March 31, 2015 were as follows:
	Three Months Ended March 31, 2015
	Details about Accumulated Other Comprehensive Income (Loss) Components		Amount Reclassified from Accumulated Other Comprehensive Income (Loss)				Affected Line Item in the Statement where Net Income (Loss) is Presented
			(In thousands)
	Gains and losses on cash flow hedges
	Interest rate swap		$	(388	)		Interest (expense)
			167				Tax (expense) or benefit
			$	(221	)		Net of tax

SEGMENT_AND_GEOGRAPHIC_INFORMA1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Total Revenue By Major Geographic Area	Net sales and profit by reportable segment for the three months ended March 31, 2015 and 2014 are as follows:
			Three Months Ended March 31,
			2015				2014
			(In thousands)
	Segment Net Sales
	Specialty Surgical Solutions		$	140,058			$	127,195
	Orthopedics and Tissue Technologies		61,367				54,589
	Spine		32,240				33,275
	Total revenues		$	233,665			$	215,059
	Segment Profit
	Specialty Surgical Solutions		$	60,332			$	48,297
	Orthopedics and Tissue Technologies		19,582				17,001
	Spine		3,125				2,748
	Segment profit		83,039				68,046
	Amortization		(3,535		)		-3,033
	Corporate and other		(62,716		)		(56,275		)
	Operating income (loss)		$	16,788			$	8,738
	The Company attributes revenues to geographic areas based on the location of the customer. There are certain revenues managed by the various U.S. segments that are generated from non-U.S. customers and therefore are included in Europe and the Rest of World revenues below. Total revenue by major geographic area consisted of the following:
		Three Months Ended March 31,
		2015				2014
		(In thousands)
	United States	$	180,960			$	163,382
	Europe	26,764				25,324
	Rest of World	25,941				26,353
	Total Revenues	$	233,665			$	215,059

BUSINESS_ACQUISITIONS_Narrativ

BUSINESS ACQUISITIONS - Narrative (Details) (USD $)	3 Months Ended		0 Months Ended			3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 05, 2014	Oct. 27, 2014	Jan. 15, 2014	Jun. 30, 2014
Business Acquisition [Line Items]
Impairment of intangible assets	$409,000	$600,000
Metasurg
Business Acquisition [Line Items]
Consideration for acquisition			27,200,000
Payments for acquisition			26,500,000
Contingent consideration acquisition			700,000
Business acquisition, additional cash consideration payable upon completion of milestones			38,500,000
Fair value inputs, discount rate			19.90%
Revenue of acquired company since acquisition	1,600,000
Net assets acquired	27,150,000
Medtronic MicroFrance
Business Acquisition [Line Items]
Payments for acquisition				60,100,000
Revenue of acquired company since acquisition	5,800,000
Adjustment of consideration for acquisition	-1,500,000			1,500,000
Adjustment to goodwill				800,000
Net assets acquired	60,067,000
Confluent Surgical, Inc.
Business Acquisition [Line Items]
Contingent consideration acquisition					20,900,000
Business acquisition, additional cash consideration payable upon completion of milestones					30,000,000
Fair value inputs, discount rate					2.20%
Revenue of acquired company since acquisition	17,700,000	14,100,000
Net assets acquired	255,895,000				255,895,000
Payments to acquire business interest					231,000,000
Payments for transitional supply agreements from acquisition					4,000,000
Contingent liability extension period					2 years
Consideration liability, number of required days for extension					180 days
Contingent liability, period of consideration arrangement					5 years
Contingent liability, period of transitional supply price increases					3 years
Impairment of intangible assets	600,000
Fair value input, probability of event					95.00%
Incremental increase in contingent liability					300,000
Incremental decrease in contingent liability					400,000
Confluent Surgical, Inc. | Potential Cash Consideration Fair Value
Business Acquisition [Line Items]
Business acquisition, additional cash consideration payable upon completion of milestones					25,000,000
Confluent Surgical, Inc. | Cash Consideration Two
Business Acquisition [Line Items]
Business acquisition, additional cash consideration payable upon completion of milestones					5,000,000
Deferred Tax Liability | Confluent Surgical, Inc.
Business Acquisition [Line Items]
MicroFrance working capital and purchase price adjustments						$12,400,000

BUSINESS_ACQUISITIONS_Schedule

BUSINESS ACQUISITIONS - Schedule of Purchase Price Allocation (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Jan. 15, 2014
Business Acquisition [Line Items]
Goodwill	354,202	$363,888
Metasurg
Business Acquisition [Line Items]
Inventory	4,730
Fixed assets	1,171
Goodwill	469
Net assets acquired	27,150
Metasurg | In Process Research and Development
Business Acquisition [Line Items]
Indefinite intangible assets	190
Metasurg | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Finite intangible assets	20,590
Metasurg | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Weighted average useful life	8 years
Metasurg | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Weighted average useful life	14 years
Medtronic MicroFrance
Business Acquisition [Line Items]
Cash	2,195
Inventory	3,155
Inventory deposit	620
Fixed assets	3,675
Other current assets	5,025
Goodwill	16,607
Total assets acquired	65,977
Accounts payable and other liabilities	5,910
Net assets acquired	60,067
Medtronic MicroFrance | Trade Names
Business Acquisition [Line Items]
Finite intangible assets	11,990
Medtronic MicroFrance | Trade Names | Maximum
Business Acquisition [Line Items]
Weighted average useful life	20 years
Medtronic MicroFrance | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Finite intangible assets	4,580
Medtronic MicroFrance | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Weighted average useful life	15 years
Medtronic MicroFrance | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Weighted average useful life	16 years
Medtronic MicroFrance | Customer relationships
Business Acquisition [Line Items]
Finite intangible assets	18,130
Medtronic MicroFrance | Customer relationships | Minimum
Business Acquisition [Line Items]
Weighted average useful life	12 years
Medtronic MicroFrance | Customer relationships | Maximum
Business Acquisition [Line Items]
Weighted average useful life	16 years
Confluent Surgical, Inc.
Business Acquisition [Line Items]
Inventory deposit	4,000
Fixed assets	438
Deferred tax assets - long term	12
Goodwill	105,331
Total assets acquired	349,981
Contingent supply liability	5,891
Other	731
Deferred tax liabilities - long term	87,464
Net assets acquired	255,895		255,895
Confluent Surgical, Inc. | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Weighted average useful life	3 years
Confluent Surgical, Inc. | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Weighted average useful life	20 years
Confluent Surgical, Inc. | Developed Technology Rights
Business Acquisition [Line Items]
Finite intangible assets	239,800
Confluent Surgical, Inc. | Other Intangible Assets
Business Acquisition [Line Items]
Finite intangible assets	400

BUSINESS_ACQUISITIONS_Schedule1

BUSINESS ACQUISITIONS - Schedule of Contingent Consideration (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Business Acquisition, Contingent Consideration [Roll Forward]
Loss from increase in fair value of contingent consideration liabilities	$125	$128
Level 3 | Potential Cash Consideration Fair Value
Business Acquisition, Contingent Consideration [Roll Forward]
Balance as of January 1, 2015			22,008
Fair value at March 31, 2015	22,133		22,008
Level 3 | Selling, General and Administrative Expenses | Potential Cash Consideration Fair Value
Business Acquisition, Contingent Consideration [Roll Forward]
Loss from increase in fair value of contingent consideration liabilities	$125

BUSINESS_ACQUISITIONS_Pro_Form

BUSINESS ACQUISITIONS - Pro Forma Information (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Business Acquisition [Line Items]
Total revenue	$225,509
Net income	$5,572
Basic (in dollars per share)	$0.17

INVENTORIES_Inventory_Net_Deta

INVENTORIES (Inventory, Net) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory, Net [Abstract]
Finished goods	$143,866	$150,483
Work-in process	53,168	50,166
Raw materials	36,009	36,465
Inventories, net	$233,043	$237,114

GOODWILL_AND_OTHER_INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill at December 31, 2014		$363,888
Balance, March 31, 2015	354,202	363,888
Orthopedics and Tissue Technologies
Goodwill [Line Items]
Goodwill, gross		81,650
Accumulated impairment losses		0
Goodwill [Roll Forward]
Goodwill at December 31, 2014	81,650
MicroFrance working capital and purchase price adjustments	0
Goodwill impairment charge	0
Foreign currency translation	-2,016
Balance, March 31, 2015	79,634
Spine
Goodwill [Line Items]
Goodwill, gross		409
Accumulated impairment losses		0
Goodwill [Roll Forward]
Goodwill at December 31, 2014	409
MicroFrance working capital and purchase price adjustments	0
Goodwill impairment charge	-409
Foreign currency translation	0
Balance, March 31, 2015	0
U.S. Spine And Other
Goodwill [Line Items]
Goodwill, gross		363,888
Accumulated impairment losses		0
Goodwill [Roll Forward]
Goodwill at December 31, 2014	363,888
MicroFrance working capital and purchase price adjustments	-828
Goodwill impairment charge	-409
Foreign currency translation	-8,449
Balance, March 31, 2015	354,202
Specialty Surgical Solutions
Goodwill [Line Items]
Goodwill, gross		281,829
Accumulated impairment losses		0
Goodwill [Roll Forward]
Goodwill at December 31, 2014	281,829
MicroFrance working capital and purchase price adjustments	-828
Goodwill impairment charge	0
Foreign currency translation	-6,433
Balance, March 31, 2015	$274,568

GOODWILL_AND_OTHER_INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Components of Company's Identifiable Intangible Assets (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
Cost	$633,026,000		$639,648,000
Accumulated Amortization	-185,602,000		-180,189,000
Net	447,424,000		459,459,000
Completed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	18 years		18 years
Cost	343,942,000		345,082,000
Accumulated Amortization	-67,172,000		-62,920,000
Net	276,770,000		282,162,000
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	12 years		12 years
Cost	158,546,000		162,031,000
Accumulated Amortization	-88,817,000		-87,653,000
Net	69,729,000		74,378,000
Trademarks/brand names
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	34 years		34 years
Cost	42,713,000		44,520,000
Accumulated Amortization	-15,457,000		-15,755,000
Net	27,256,000		28,765,000
Trademarks/brand names indefinite
Acquired Finite-Lived Intangible Assets [Line Items]
Cost	48,484,000		48,484,000
Accumulated Amortization	0		0
Net	48,484,000		48,484,000
Supplier relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	27 years		27 years
Cost	34,721,000		34,721,000
Accumulated Amortization	-11,166,000		-10,809,000
Net	23,555,000		23,912,000
All other
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life	4 years	[1]	4 years	[1]
Cost	4,620,000	[1]	4,810,000	[1]
Accumulated Amortization	-2,990,000	[1]	-3,052,000	[1]
Net	1,630,000	[1]	1,758,000	[1]
In Process Research and Development
Acquired Finite-Lived Intangible Assets [Line Items]
Other Indefinite-lived Intangible Assets	$1,400,000		$1,400,000
[1]	At March 31, 2015 and December 31, 2014, all other included in-process research and development ("IPR&D") of $1.4 million in both periods, which was indefinite-lived.

GOODWILL_AND_OTHER_INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Goodwill [Line Items]
Impairment of intangible assets	$409,000	$600,000
Annual amortization expense expected to approximate in 2015	31,800,000
Annual amortization expense expected to approximate in 2016	29,600,000
Annual amortization expense expected to approximate in 2017	27,600,000
Annual amortization expense expected to approximate in 2018	27,200,000
Annual amortization expense expected to approximate in 2019	26,500,000
Confluent Surgical, Inc.
Goodwill [Line Items]
Impairment of intangible assets	$600,000

DEBT_Narrative_Details

DEBT -Narrative (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jul. 02, 2014	Jun. 15, 2011	Dec. 31, 2014
Debt Instrument [Line Items]
Amortization of debt issuance costs	$530,000	$608,000
Term loan, amount outstanding	150,000,000
Carrying amount of liability	215,177,000				213,121,000
July 2014 Amendment
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			900,000,000
Additional commitments			200,000,000
Cash balance threshold above which excess amount is not subject to any restriction of use or investment			40,000,000
Deferred finance costs, gross			3,200,000
Amortization of debt issuance costs			300,000
July 2014 Amendment | Minimum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage			0.15%
July 2014 Amendment | Maximum
Debt Instrument [Line Items]
Line of credit, commitment fee percentage			0.30%
Proceeds from lines of credit			422,000,000
July 2014 Amendment | Standby Letters of Credit
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			60,000,000
July 2014 Amendment | Revolving Credit Facility
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			750,000,000
Proceeds from lines of credit			272,000,000
July 2014 Amendment | Swingline Loan
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			60,000,000
Term Loan
Debt Instrument [Line Items]
Weighted average interest rate on debt	1.70%
Long-term debt, fair value	141,300,000
June 2011 Amendment | Revolving Credit Facility
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			600,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility outstanding	251,900,000				266,900,000
Weighted average interest rate on debt					1.70%
Available borrowings under senior secured revolving credit facility	498,100,000
Line of credit facility, fair value of amount outstanding	235,800,000
2016 Convertible Senior Notes
Debt Instrument [Line Items]
Principal amount outstanding	230,000,000			230,000,000	230,000,000
Interest rate on debt				1.63%
Portion of the debt proceeds that was classified as equity at the time of the offering				43,200,000
Effective interest rate implicit in the liability component				5.60%
Carrying amount of liability	215,200,000				213,100,000
Unamortized discount	14,800,000				16,900,000
Fair value of outstanding borrowings	272,300,000
Common stock based on initial conversion rate ratio (in shares)				17.4092
Principal amount to be considered for conversion purpose				1,000
Initial conversion price, per share				$57.44
Maximum selling price of company's common stock				150.00%
Principal amount of notes per average trading price				1,000
Maximum average conversion value of the Notes				98.00%
Strike price of the call transaction (in dollars per share)				$57.44
Strike price of warrant transactions (in dollars per share)				$70.05
Term Loan | July 2014 Amendment
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity			150,000,000
Proceeds from lines of credit			$150,000,000
Federal Funds | July 2014 Amendment
Debt Instrument [Line Items]
Interest rates available to the Company at its option			0.50%
(LIBOR) | July 2014 Amendment
Debt Instrument [Line Items]
Interest rates available to the Company at its option			1.00%
Eurodollar | July 2014 Amendment | Minimum
Debt Instrument [Line Items]
Interest rates available to the Company at its option			1.00%
Eurodollar | July 2014 Amendment | Maximum
Debt Instrument [Line Items]
Interest rates available to the Company at its option			1.75%

DEBT_5_year_payout_table_Detai

DEBT -5 year payout table (Details) (Term Loan, USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Term Loan
Term loan maturities [Line Items]
Long-term Debt, Maturities, Repayments of Principal in 2015	$3,750
Long-term Debt, Maturities, Repayments of Principal in 2016	9,375
Long-term Debt, Maturities, Repayments of Principal in 2017	13,125
Long-term Debt, Maturities, Repayments of Principal in 2018	15,000
Long-term Debt, Maturities, Repayments of Principal in 2019	108,750
Secured Debt	$150,000

DEBT_Components_of_Interest_Ex

DEBT - Components of Interest Expense (Detail) (2016 Convertible Senior Notes, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
2016 Convertible Senior Notes
Debt Instrument [Line Items]
Amortization of the discount on the liability component	$1,859	$1,666
Cash interest related to the contractual interest coupon	845	801
Total	$2,704	$2,467

DERIVATIVE_INSTRUMENTS_Narrati

DERIVATIVE INSTRUMENTS - Narrative (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Derivative [Line Items]
Interest rate swap expiration date	August 10, 2015
Gain (loss) on hedging ineffectiveness	$0	$0
Interest Rate Swap
Derivative [Line Items]
Pretax losses expected to be reclassified from AOCI in next 12 months	$500,000

DERIVATIVE_INSTRUMENTS_Summary

DERIVATIVE INSTRUMENTS - Summary of Fair Value in Balance Sheet for Derivatives Designated Hedging Instruments (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Fair value of derivative liabilities	$527,000	$898,000
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Notional amount derivative instruments	93,800,000	97,500,000
Reduction in notional amount of interest rate derivatives in next twelve months	93,800,000
Interest Rate Swap | Accrued expenses and other current liabilities
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Fair value of derivative liabilities	$527,000	$898,000

DERIVATIVE_INSTRUMENTS_Effect_

DERIVATIVE INSTRUMENTS - Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	($898)	($2,439)
Amount of Loss Recognized in AOCI- Effective Portion	-18	-109
Amount of Loss Reclassified from AOCI into Earnings-Effective Portion	-389	-451
Balance in AOCI End of Period	-527	-2,097
Interest Expense | Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	-898	-2,439
Amount of Loss Recognized in AOCI- Effective Portion	-18	-109
Amount of Loss Reclassified from AOCI into Earnings-Effective Portion	-389	-451
Balance in AOCI End of Period	($527)	($2,097)

STOCKBASED_COMPENSATION_Narrat

STOCK-BASED COMPENSATION - Narrative (Detail) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period, net of forfeitures	78,336
Requisite service periods of awards, in years	3 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period, in years	4 years
Total unrecognized compensation costs	2.7
Weighted-average period for cost recognition, in years	3 years
Restricted stock awards/stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period, in years	3 years
Total unrecognized compensation costs	20.3
Weighted-average period for cost recognition, in years	2 years
Awards granted during period	117,763
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted during period	64,770
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years	8 years
Directors and certain executive officers | Minimum | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years	8 years
Directors and certain executive officers | Maximum | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period, in years	10 years

TREASURY_STOCK_Additional_Info

TREASURY STOCK (Additional Information) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Oct. 28, 2014
Accelerated Share Repurchases [Line Items]
Stock repurchased during period, shares	0	0
Amount available for share repurchase under this latest authorization	$75,000,000
October 2012 Authorization
Accelerated Share Repurchases [Line Items]
Stock repurchase program, authorized amount			$75,000,000

INCOME_TAXES_Narrative_Details

INCOME TAXES - Narrative (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Tax [Line Items]
Reported tax rate	33.50%	44.50%
Minimum
Income Tax [Line Items]
Effective tax rate estimate	29.00%
Maximum
Income Tax [Line Items]
Effective tax rate estimate	30.00%
Foreign tax authority
Income Tax [Line Items]
Income tax reconciliation, settlements with tax authority		0.8

INCOME_TAXES_Summary_of_Effect

INCOME TAXES - Summary of Effective Tax Rate (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Reported tax rate	33.50%	44.50%

NET_INCOME_PER_SHARE_Narrative

NET INCOME PER SHARE - Narrative (Detail)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options, shares outstanding (in shares)	1.4	1.3
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation as their effect would be anti-dilutive	0.2

NET_INCOME_PER_SHARE_Basic_and

NET INCOME PER SHARE - Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Basic net income per share:
Net income	$8,384	$2,206
Weighted average common shares outstanding (in shares)	32,736	32,275
Basic net income per common share (in dollars per share)	$0.26	$0.07
Diluted net income per share:
Net income	$8,384	$2,206
Weighted average common shares outstanding (in shares)	32,736	32,275
Effect of dilutive securities:
2016 Convertible notes (in shares)	30	0
Stock options and restricted stock (in shares)	576	493
Weighted average common shares for diluted earnings per share (in shares)	33,342	32,768
Diluted net income per common share (in dollars per share)	$0.25	$0.07

COMPREHENSIVE_LOSS_INCOME_Sche

COMPREHENSIVE (LOSS) INCOME - Schedule of Comprehensive Loss Income (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Net income	$8,384	$2,206
Foreign currency translation adjustment	-24,393	819
Change in unrealized gain on derivatives, net of tax	211	195
Pension liability adjustment, net of tax	54	-14
Comprehensive (loss) income	($15,744)	$3,206

COMPREHENSIVE_LOSS_INCOME_Sche1

COMPREHENSIVE (LOSS) INCOME (Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	($23,488)
Other comprehensive income before reclassifications	-24,349
Amounts reclassified from accumulated other comprehensive income	221
Net current-period other comprehensive income	-24,128
Ending balance	-47,616
Gains and Losses on Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	-512
Other comprehensive income before reclassifications	-10
Amounts reclassified from accumulated other comprehensive income	221
Net current-period other comprehensive income	211
Ending balance	-301
Defined Benefit Pension Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	-906
Other comprehensive income before reclassifications	54
Amounts reclassified from accumulated other comprehensive income	0
Net current-period other comprehensive income	54
Ending balance	-852
Foreign Currency Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	-22,070
Other comprehensive income before reclassifications	-24,393
Amounts reclassified from accumulated other comprehensive income	0
Net current-period other comprehensive income	-24,393
Ending balance	($46,463)

COMPREHENSIVE_LOSS_INCOME_Recl

COMPREHENSIVE (LOSS) INCOME (Reclassification Adjustment from AOCI) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)	($5,492)	($5,142)
Tax (expense) or benefit	-4,233	-1,769
Net income	8,384	2,206
Reclassification out of Accumulated Other Comprehensive Income | Gains and Losses on Cash Flow Hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Tax (expense) or benefit	167
Net income	-221
Reclassification out of Accumulated Other Comprehensive Income | Gains and Losses on Cash Flow Hedges | Interest Rate Swap
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)	($388)

SEGMENT_AND_GEOGRAPHIC_INFORMA2

SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of reportable segments	3
Specialty Surgical Solutions
Segment Reporting Information [Line Items]
Number of products offered	60,000

SEGMENT_AND_GEOGRAPHIC_INFORMA3

SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Revenues	$233,665	$215,059
Operating income	16,788	8,738
Intangible asset amortization	-3,535	-3,033
Operating Segments
Segment Reporting Information [Line Items]
Operating income	83,039	68,046
Operating Segments | Specialty Surgical Solutions
Segment Reporting Information [Line Items]
Revenues	140,058	127,195
Operating income	60,332	48,297
Operating Segments | Orthopedics and Tissue Technologies
Segment Reporting Information [Line Items]
Revenues	61,367	54,589
Operating income	19,582	17,001
Operating Segments | Spine
Segment Reporting Information [Line Items]
Revenues	32,240	33,275
Operating income	3,125	2,748
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Operating income	($62,716)	($56,275)

SEGMENT_AND_GEOGRAPHIC_INFORMA4

SEGMENT AND GEOGRAPHIC INFORMATION - Total Revenue by Major Geographic Area (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Revenues	$233,665	$215,059
United States
Segment Reporting Information [Line Items]
Revenues	180,960	163,382
Europe
Segment Reporting Information [Line Items]
Revenues	26,764	25,324
Rest of World
Segment Reporting Information [Line Items]
Revenues	$25,941	$26,353